A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2014
At a glance
- Drugs Vanutide cridificar (Primary) ; QS 21
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 29 Jan 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 11 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.